CompletedPhase 3NCT03172299
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
Studying Neovascular glaucoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Principal Investigator
- Stéphanie BAILLIF, PrCentre Hospitalier Universitaire de Nice
- Intervention
- Aflibercept Injection(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2025
Study locations (1)
- CHU de Nice, Nice, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03172299 on ClinicalTrials.govOther trials for Neovascular glaucoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07201415Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular GlaucomaZhongnan Hospital
- ACTIVE NOT RECRUITINGNANCT05316142Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular GlaucomaIran University of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE1NCT04844619KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) TrialSun Yat-sen University
- RECRUITINGNCT04519619Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)Bayer